ImmunityBio, Inc.
IBRX
Clasificación en acciones
#2133
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Precio por acción
$9.08
Última sincronización: 2026-10-16
Capitalización bursátil
$9.62B
Cambio (1 día)
-9.25%
Cambio (1 año)
278.13%
País
US
Comercio ImmunityBio, Inc. (IBRX)
Categoría
Healthcare
Margen Operativo de ImmunityBio, Inc. (IBRX)
Margen Operativo al October 2026 TTM: -151.88%
Según los informes financieros más recientes y el precio de las acciones de ImmunityBio, Inc., el margen operativo actual (TTM) es -151.88%. Al final de 2023, el margen operativo era -58,239.55%.
Historial de Margen Operativo de ImmunityBio, Inc. desde 2013 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | -151.88% | -93.49% |
| 2024 | -2,334.23% | -95.99% |
| 2023 | -58,239.55% | -60.21% |
| 2022 | -146,374.17% | 313.93% |
| 2021 | -35,361.88% | -3.14% |
| 2020 | -36,509.09% | 414.51% |
| 2019 | -7,095.87% | -96.61% |
| 2018 | -209,338.30% | -4.96% |
| 2017 | -220,266.67% | -22.15% |
| 2016 | -282,954.55% | 179.55% |
| 2015 | -101,218.64% | 10,344.49% |
| 2014 | -969.11% | 156.26% |
| 2013 | -378.17% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -100.25% |
US
|
|
| -149.01% | -99.02% |
US
|
|
| 25.57% | -100.17% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.19% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.